Results 21 to 30 of about 8,219 (198)

Treatment of Leukemia Cutis Secondary to T-Cell Prolymphocytic Leukemia With Upadacitinib. [PDF]

EJHaem
eJHaem, Volume 7, Issue 5, October 2026.
Fraser K, Langille C, Chen LYC, Purdy K.
europepmc   +2 more sources

Upadacitinib tartrate in rheumatoid arthritis

, 2020
In rheumatoid arthritis (RA) there is an unmet therapeutic need, as a substantial proportion of patients does not achieve low disease activity or remission despite the use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or ...
Bogdanos, Dimitrios P., Sakkas, Lazaros, Stamatis, P., Bogdanos, D.P., Stamatis, Pavlos, Sakkas, L.I.   +5 more
core   +2 more sources

Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease [PDF]

Upadacitinib has recently been approved for treating Crohn's disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with difficult-to-treat CD being cared for at clinical centers across ...
Lorenzo Bertani, Paola Balestrieri, Marzo, Manuela, Soriano, Alessandra, Conforti, Francesco Simone, Cristina Bezzio, Principi, Maria Beatrice, Carolina Cavalli, Savarino, Edoardo V, Angela Variola, Bodini, Giorgia, Alessandro Armuzzi, Casini, Valentina, Armuzzi, Alessandro, Michele Campigotto, Variola, Angela, Silvio Danese, Balestrieri, Paola, Manuela Marzo, Aratari, Annalisa, Barberio, Brigida, Annalisa Aratari, Cavalli, Carolina, Calabrese, Emma, Savarino Edoardo, Cappello, Maria, Andrea Michielan, Danese, Silvio, Maria Cappello, Ceccarelli, Linda, Valentina Casini, Bertani, Lorenzo, Alessandra Soriano, Mauro Mastronardi, Federica Furfaro, Franco Scaldaferri, Giorgia Bodini, Giuseppe Biscaglia, Campigotto, Michele, Emma Calabrese, Linda Ceccarelli, Flavio Andrea Caprioli, Mastronardi, Mauro, Furfaro, Federica, Caprioli, Flavio Andrea, Saibeni, Simone, Franchellucci, Gianluca, Biscaglia, Giuseppe, Michielan, Andrea, Simone Saibeni, Bezzio, Cristina, Francesco Simone Conforti, Scaldaferri, Franco, Maria Beatrice Principi, Gianluca Franchellucci, Barberio Brigida   +55 more
core   +4 more sources

Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study. [PDF]

J Clin Med
Background/Objectives: Upadacitinib is recommended for moderate-to-severe ulcerative colitis (UC); however, data regarding its effectiveness and long-term outcomes in large patient populations remain limited.
Maeyashiki C, Tamaki N, Tanaka Y, Yasui Y, Tsuchiya K, Nakanishi H, Kurosaki M.   +6 more
europepmc   +2 more sources

Upadacitinib [PDF]

Reactions Weekly, 2020
Ein weiterer Januskinase-Hemmer, der bei der rheumatoiden Arthritis eingesetzt werden kann. Bisher vorliegende Vergleiche mit Placebo, Methotrexat und Adalimumab lassen eine gute Wirksamkeit der neuen Substanz annehmen; es sind aber erst wenig Langzeitdaten verfügbar.
openaire   +2 more sources

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. [PDF]

, 2022
BACKGROUND There is a great unmet need for advanced therapies that provide rapid, robust, and sustained disease control for patients with ulcerative colitis.
Pangan, Aileen L., Sanchez Gonzalez, Yuri, Weinreich, Michael A., Sandborn, William J, Panaccione, Remo, D'Haens, Geert, Reinisch, Walter, Lindsay, James O., Siffledeen, Jesse, Juillerat, Pascal, Loftus, Edward V., Higgins, Peter D R, Higgins, Peter D. R., Gonzalez, Yuri Sanchez, Vermeire, S. verine, Pangan, Aileen L, Zhou, Wen, Chen, Min-Hu, Greenbloom, Susan, Xie, Wangang, Higgins, Peter D.R., Panés, Julian, Loftus, Edward V, Danese, Silvio, Hébuterne, Xavier, Sandborn, William J., Liu, John, Huang, Bidan, Weinreich, Michael A, Lindsay, James O, Nakase, Hiroshi, Vermeire, Séverine   +31 more
core   +1 more source

Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease

RMD Open
Objectives Evaluate the risks and benefits of upadacitinib 15 mg vs adalimumab in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate based on cardiovascular (CV) risk.Methods In SELECT-COMPARE, patients received upadacitinib ...
Roy Fleischmann, Stephen Hall, Gerd R Burmester, Eduardo Mysler, Peter Taylor, Tianming Gao, Sander Strengholt, Bettina Wick-Urban, Andrew Garrison, Irina Fish   +9 more
doaj   +1 more source

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)

Arthritis Research & Therapy, 2021
Background The objective of the study was to evaluate the efficacy and safety of upadacitinib over 84 weeks in Japanese patients with active rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease-modifying anti-rheumatic ...
Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, Motohiro Oribe, Mitsuhiro Kawano, Masayuki Yokoyama, Aileen L. Pangan, Yuko Konishi, Sebastian Meerwein, Yoshiya Tanaka   +9 more
doaj   +1 more source

Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial

Arthritis Research & Therapy
Background To evaluate the efficacy and safety of upadacitinib monotherapy versus methotrexate (MTX) monotherapy over 5 years among MTX-naïve patients with moderately to severely active rheumatoid arthritis (RA) in the long-term extension (LTE) of the ...
Ronald van Vollenhoven, Vibeke Strand, Tsutomu Takeuchi, Nilmo Chávez, Pablo Mannucci Walter, Atul Singhal, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, Sara K. Penn, Heidi S. Camp, Jacob Aelion   +12 more
doaj   +1 more source

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss, Judith A. Smith, Robert A. Colbert, Erin Treemarcki, Michael H. Weisman, Walter P. Maksymowych, Hermine I. Brunner, for the Childhood Arthritis and Rheumatology Research Alliance, Spondyloarthritis Research and Treatment Network, and Pediatric Rheumatology Collaborative Study Group Advisory Council   +9 more
wiley   +1 more source